Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/21/2026

1. SPY
2. WBD
3. NVDA
4. PSKY
5. TSLA
6. AMD
7. USO
8. META
9. AMC
10. ACN

Go back to Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer
GLAXOSMITHKLINE PLC (NYSE: GSK) Delayed: 51.25 +1.03 (2.05%)
Previous Close $50.22    52 Week High $45.58 
Open $50.75    52 Week Low $37.82 
Day High $51.27    P/E N/A 
Day Low $50.46    EPS $0.00 
Volume 1,675,743       

GLAXOSMITHKLINE PLC (NYSE: GSK) Delayed: 51.25 +1.03 (2.05%)
Previous Close $50.22    52 Week High $45.58 
Open $50.75    52 Week Low $37.82 
Day High $51.27    P/E N/A 
Day Low $50.46    EPS $0.00 
Volume 1,675,743